The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Open accessAbstract
Immune checkpoint inhibitors (ICI) used for cancer immunotherapy were shown to boost the existing anti-tumor immune response by preventing the inhibition of T cells by tumor cells. Antibodies targeting two negative immune checkpoint pathways, namely cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death-ligand 1 (PD-L1), have been approved first for patients with melanoma, squamous non-small cell lung cancer (NSCLC), and renal cell carcinoma. Clinical trials are ongoing to verify the efficiency of these antibodies for other cancer types and to evaluate strategies to block other checkpoint molecules. However, a number of patients do not respond to this treatment possibly due to profound immunosuppression, which is mediated partly by myeloid-derived suppressor cells (MDSC). This heterogeneous population of immature myeloid cells can strongly inhibit anti-tumor activities of T and NK cells and stimulate regulatory T cells (Treg), leading to tumor progression. Moreover, MDSC can contribute to patient resistance to immune checkpoint inhibition. Accumulating evidence demonstrates that the frequency and immunosuppressive function of MDSC in cancer patients can be used as a predictive marker for therapy response. This review focuses on the role of MDSC in immune checkpoint inhibition and provides an analysis of combination strategies for MDSC targeting together with ICI to improve their therapeutic efficiency in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationMyeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Self-citationNoman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Myeloid-derived suppressor cells coming of age
Veglia, F., Perego, M., & Gabrilovich, D. (2018) · Nature Immunology · doi:10.1038/s41590-017-0022-x · Cited by 1,767
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,174
L-arginine availability regulates T-lymphocyte cell-cycle progression.
Rodriguez, P. C., Quiceno, D. G., & Ochoa, A. C. (2007) · Blood · doi:10.1182/blood-2006-06-031856 · Cited by 926
Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., & Ostrand-Rosenberg, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.977 · Cited by 847
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
Condamine, T., & Gabrilovich, D. I. (2011) · Trends in Immunology · doi:10.1016/j.it.2010.10.002 · Cited by 845
Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793
Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti, L., Bronte, V., & Borrello, I. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061104 · Cited by 766
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Platten, M., Wick, W., & Van den Eynde, B. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0569 · Cited by 703
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
Yu, J., Du, W., Yan, F., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., & Ren, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201449 · Cited by 606
Gabitass, R. F., Annels, N. E., Stocken, D. D., Pandha, H. A., & Middleton, G. W. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1028-0 · Cited by 575
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Emens, L. A., Ascierto, P. A., Darcy, P. K., Demaria, S., Eggermont, A. M. M., Redmond, W. L., Seliger, B., & Marincola, F. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.035 · Cited by 566
Mirza, N., Fishman, M., Fricke, I., Dunn, M., Neuger, A. M., Frost, T. J., Lush, R. M., Antonia, S., & Gabrilovich, D. I. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1690 · Cited by 564
Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1508-5 · Cited by 560
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541 · cited 1×
“It was shown by three more studies that a lower frequency of circulating MDSC at baseline can be used as a predictive marker for ipilimumab treatment of malignant melanoma patients (14, 15, 63).”
BackgroundMyeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
Ostrand-Rosenberg, S. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0855-8 · Cited by 521
Ostrand-Rosenberg, S., & Fenselau, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701019 · Cited by 509
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
Vasquez-Dunddel, D., Pan, F., Zeng, Q., Gorbounov, M., Albesiano, E., Fu, J., Blosser, R. L., Tam, A. J., Bruno, T., Zhang, H., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60083 · Cited by 507
Myeloid-Derived Suppressor Cells
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.04.002 · Cited by 482
Pan, P.-Y., Ma, G., Weber, K. J., Ozao-Choy, J., Wang, G., Yin, B., Divino, C. M., & Chen, S.-H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1882 · Cited by 467
Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5272 · Cited by 445 · cited 1×
“Systemic administration of the STAT3 antisense oligonucleotide inhibitor AZD9150 was already tested in a phase I clinical trial in patients with lung cancer and lymphoma (85).”
BackgroundMechanism of All- Trans Retinoic Acid Effect on Tumor-Associated Myeloid-Derived Suppressor Cells
Nefedova, Y., Fishman, M., Sherman, S., Wang, X., Beg, A. A., & Gabrilovich, D. I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2593 · Cited by 423
Chun, E., Lavoie, S., Michaud, M., Gallini, C. A., Kim, J., Soucy, G., Odze, R., Glickman, J. N., & Garrett, W. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.024 · Cited by 402 · cited 1×
“MDSC have been identified to expand and play an important role in various cancer types, for example, in patients with melanoma (15, 21–24), multiple myeloma (25), hepatocellular carcinoma (26), NSCLC (27), renal cell carcinoma (28), breast cancer (29), prostate cancer (30), and colorectal cancer (31).”
BackgroundPlasticity of myeloid-derived suppressor cells in cancer
Tcyganov, E., Mastio, J., Chen, E., & Gabrilovich, D. I. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.009 · Cited by 398
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Di Mitri, D., Toso, A., Chen, J. J., Sarti, M., Pinton, S., Jost, T. R., D’Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., et al. (2014) · Nature · doi:10.1038/nature13638 · Cited by 388
Myeloid‐derived suppressor cell heterogeneity in human cancers
Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., & Bronte, V. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12469 · Cited by 386
Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G. V., & Kiessling, R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3767 · Cited by 382
Lesokhin, A. M., Hohl, T. M., Kitano, S., Cortez, C., Hirschhorn-Cymerman, D., Avogadri, F., Rizzuto, G. A., Lazarus, J. J., Pamer, E. G., Houghton, A. N., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1792 · Cited by 378
Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373
Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367 · cited 1×
“It was shown by three more studies that a lower frequency of circulating MDSC at baseline can be used as a predictive marker for ipilimumab treatment of malignant melanoma patients (14, 15, 63).”
BackgroundSelf-citationMeyer, C., Sevko, A., Ramacher, M., Bazhin, A. V., Falk, C. S., Osen, W., Borrello, I., Kato, M., Schadendorf, D., Baniyash, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108121108 · Cited by 346
Self-citationUmemura, N., Saio, M., Suwa, T., Kitoh, Y., Bai, J., Nonaka, K., Ouyang, G.-F., Okada, M., Balazs, M., Adany, R., et al. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0907611 · Cited by 346
TCR ζ-chain downregulation: curtailing an excessive inflammatory immune response
Baniyash, M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1434 · Cited by 344
Iclozan, C., Antonia, S., Chiappori, A., Chen, D.-T., & Gabrilovich, D. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1396-8 · Cited by 317
Liu, C.-Y., Wang, Y.-M., Wang, C.-L., Feng, P.-H., Ko, H.-W., Liu, Y.-H., Wu, Y.-C., Chu, Y., Chung, F.-T., Kuo, C.-H., et al. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0634-0 · Cited by 313
Nirschl, C. J., & Drake, C. G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1972 · Cited by 306
The regulation of MMP targeting to invadopodia during cancer metastasis
Jacob, A., & Prekeris, R. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00004 · Cited by 299
Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer
Vuk‐Pavlović, S., Bulur, P. A., Lin, Y., Qin, R., Szumlanski, C. L., Zhao, X., & Dietz, A. B. (2010) · The Prostate · doi:10.1002/pros.21078 · Cited by 266
Limagne, E., Euvrard, R., Thibaudin, M., Rébé, C., Derangère, V., Chevriaux, A., Boidot, R., Végran, F., Bonnefoy, N., Vincent, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3164 · Cited by 264
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis
Zhang, J., Patel, L., & Pienta, K. J. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.009 · Cited by 261
Weed, D. T., Vella, J. L., Reis, I. M., De la fuente, A. C., Gomez, C., Sargi, Z., Nazarian, R., Califano, J., Borrello, I., & Serafini, P. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1711 · Cited by 261
Weide, B., Martens, A., Zelba, H., Stutz, C., Derhovanessian, E., Di Giacomo, A. M., Maio, M., Sucker, A., Schilling, B., Schadendorf, D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2508 · Cited by 261
The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
Wolchok, J. D., & Saenger, Y. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s4-2 · Cited by 250
Sevko, A., Michels, T., Vrohlings, M., Umansky, L., Beckhove, P., Kato, M., Shurin, G. V., Shurin, M. R., & Umansky, V. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202781 · Cited by 246
Self-citationStiff, A., Trikha, P., Mundy-Bosse, B., McMichael, E., Mace, T. A., Benner, B., Kendra, K., Campbell, A., Gautam, S., Abood, D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0691 · Cited by 244
The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
Ostrand-Rosenberg, S., Horn, L. A., & Haile, S. T. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401572 · Cited by 228
Eriksson, E., Wenthe, J., Irenaeus, S., Loskog, A., & Ullenhag, G. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1037-z · Cited by 219
Brimnes, M. K., Vangsted, A. J., Knudsen, L. M., Gimsing, P., Gang, A. O., Johnsen, H. E., & Svane, I. M. (2010) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2010.02463.x · Cited by 215
Davis, R. J., Moore, E. C., Clavijo, P. E., Friedman, J., Cash, H., Chen, Z., Silvin, C., Van Waes, C., & Allen, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2534 · Cited by 213
Sade-Feldman, M., Kanterman, J., Klieger, Y., Ish-Shalom, E., Olga, M., Saragovi, A., Shtainberg, H., Lotem, M., & Baniyash, M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3104 · Cited by 201
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A. W. H., Tong, J. H., Wong, J., Chong, C. C. N., Lai, P. B. S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314032 · Cited by 201
Dominguez, G. A., Condamine, T., Mony, S., Hashimoto, A., Wang, F., Liu, Q., Forero, A., Bendell, J., Witt, R., Hockstein, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1784 · Cited by 187
Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Califano, J. A., Khan, Z., Noonan, K. A., Rudraraju, L., Zhang, Z., Wang, H., Goodman, S., Gourin, C. G., Ha, P. K., Fakhry, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1716 · Cited by 184
CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions
Blattner, C., Fleming, V., Weber, R., Himmelhan, B., Altevogt, P., Gebhardt, C., Schulze, T. J., Razon, H., Hawila, E., Wildbaum, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0348 · Cited by 182
Self-citationJiang, H., Gebhardt, C., Umansky, L., Beckhove, P., Schulze, T. J., Utikal, J., & Umansky, V. (2015) · International Journal of Cancer · doi:10.1002/ijc.29297 · Cited by 169
Self-citationKanterman, J., Sade-Feldman, M., Biton, M., Ish-Shalom, E., Lasry, A., Goldshtein, A., Hubert, A., & Baniyash, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0657 · Cited by 166
Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation
Dieterich, L. C., Ikenberg, K., Cetintas, T., Kapaklikaya, K., Hutmacher, C., & Detmar, M. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00066 · Cited by 160
Holmgaard, R., Zamarin, D., Lesokhin, A. M., Merghoub, T., & Wolchok, J. D. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.02.024 · Cited by 154
Mao, Y., Eißler, N., Blanc, K. L., Johnsen, J. I., Kogner, P., & Kiessling, R. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1912 · Cited by 151
Kim, S. H., Li, M., Trousil, S., Zhang, Y., di Magliano, M. P., Swanson, K. D., & Zheng, B. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.03.033 · Cited by 150
van Cruijsen, H., van der Veldt, A. A. M., Vroling, L., Oosterhoff, D., Broxterman, H. J., Scheper, R. J., Giaccone, G., Haanen, J. B. A. G., van den Eertwegh, A. J. M., Boven, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0656 · Cited by 148
Melanoma-induced immunosuppression and its neutralization
Umansky, V., & Sevko, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.003 · Cited by 145
Self-citationJordan, K. R., Amaria, R. N., Ramirez, O., Callihan, E., Gao, D., Borakove, M., Manthey, E., Borges, V. F., & McCarter, M. D. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1475-x · Cited by 144
Danilin, S., Merkel, A. R., Johnson, J., Johnson, R. W., Edwards, J., & Sterling, J. A. R. (2012) · OncoImmunology · doi:10.4161/onci.21990 · Cited by 143
Zhao, F., Obermann, S., von Wasielewski, R., Haile, L. A., Manns, M. P., Korangy, F., & Greten, T. F. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03105.x · Cited by 126
Chesney, J. A., Mitchell, R. A., & Yaddanapudi, K. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1116-458rrr · Cited by 124
Myeloid derived-suppressor cells: their role in cancer and obesity
Ostrand‐Rosenberg, S. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.007 · Cited by 123
Santegoets, S. J. A. M., Stam, A. G. M., Lougheed, S. M., Gall, H. E., Jooss, K. U., Sacks, N., Hege, K. M., Lowy, I., Scheper, R. J., Gerritsen, W. R., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0031-3 · Cited by 112
Meirow, Y., Kanterman, J., & Baniyash, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00523 · Cited by 99
Hassel, J. C., Jiang, H., Bender, C., Winkler, J. K., Sevko, A., Shevchenko, I., Halama, N., Dimitrakopoulou‐Strauss, A., Haefeli, W. E., Jäger, D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1326440 · Cited by 97
Self-citationClavijo, P. E., Moore, E. C., Chen, J., Davis, R. J., Friedman, J., Kim, Y., Waes, C. V., Chen, Z., & Allen, C. T. (2017) · Oncotarget · doi:10.18632/oncotarget.18437 · Cited by 97
CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. S. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1988-9 · Cited by 96
Self-citationHawila, E., Razon, H., Wildbaum, G., Blattner, C., Sapir, Y., Shaked, Y., Umansky, V., & Karin, N. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.104 · Cited by 93
Self-citationZhang, Q., Hossain, D. M. S., Duttagupta, P. A., Moreira, D., Zhao, X., Won, H., Buettner, R., Nechaev, S., Majka, M., Zhang, B., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665604 · Cited by 92
Holmgaard, R., Brachfeld, A., Gasmi, B., Jones, D. R., Mattar, M. S., Doman, T. N., Murphy, M. Y., Schaer, D., Wolchok, J. D., & Merghoub, T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1151595 · Cited by 83
Lin, S., Wang, J., Wang, L., Wen, J., Guo, Y., Qiao, W., Zhou, J., Xu, G., & Zhi, F. (2017) · Europe PMC (PubMed Central) · Cited by 82
Hypoxia-driven immunosuppression contributes to the pre-metastatic niche
Sceneay, J., Parker, B. S., Smyth, M. J., & Möller, A. (2012) · OncoImmunology · doi:10.4161/onci.22355 · Cited by 80
Immunosuppressive Microenvironment in Neuroblastoma
Pistoia, V., Morandi, F., Bianchi, G., Pezzolo, A., Prigione, I., & Raffaghello, L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00167 · Cited by 78
Four, S. D., Maenhout, S. K., Niclou, S. P., Thielemans, K., Neyns, B., & Aerts, J. L. (2016) · PubMed · Cited by 72
Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation
Umansky, V., & Sevko, A. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1164-6 · Cited by 69
Self-citationMyeloid cells in tumor inflammation
Schmid, M. C., & Varner, J. A. (2012) · Vascular Cell · doi:10.1186/2045-824x-4-14 · Cited by 68
Shen, P., Wang, A., He, M., Wang, Q., & Zheng, S. (2013) · Hepatology Research · doi:10.1111/hepr.12167 · Cited by 67
Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy
Baniyash, M. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1849-y · Cited by 62
The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients
Tobin, R. P., Davis, D. M., Jordan, K. R., & McCarter, M. D. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1016-449r · Cited by 56
Hansen, G. L., Gaudernack, G., Brunsvig, P. F., Cvancarova, M., & Kyte, J. A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1766-5 · Cited by 50
Akiyama, Y., Nonomura, C., Kondou, R., Miyata, H., Ashizawa, T., Maeda, C., Mitsuya, K., Hayashi, N., Nakasu, Y., & Yamaguchi, K. D. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3586 · Cited by 22
Checkpoint Inhibition in Head and Neck Cancer: Immune Therapeutic Options, Limitations, and Beyond
Höchst, B., & Knolle, P. A. (2017) · ORL · doi:10.1159/000455810 · Cited by 6
Cited by
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617
Metadata
- Authors
- Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-06-11
- Volume
- 9
- Pages
- 1310-1310
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2808333550
- Cited by
- 538
- References
- 100
- FWCI
- 21.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.